1. Omalizumab: an underutilized treatment option in bullous pemphigoid patients with co‐morbidities.
- Author
-
De, D., Kaushik, A., Handa, S., Mahajan, R., and Schmidt, E.
- Subjects
BULLOUS pemphigoid ,OMALIZUMAB ,CORONARY artery bypass ,MEDICAL research ,COMORBIDITY - Abstract
However, IgE also appears to be important in pathogenesis and targeting IgE autoantibodies may be an interesting and effective treatment option. Future randomized controlled trials are needed to establish omalizumab as effective and safe treatment option for BP patients and to determine which patient subset benefits most from anti-IgE therapy. Elevated serum levels of anti-BP180 and anti-BP230 IgE have been observed in 40-77% of BP patients, and anti-BP180 IgE serum levels have shown correlation with disease activity.2 By direct IF microscopy, IgE deposits have been found in the upper dermis localized on mast cells and/or eosinophils.3 It was observed that patients with IgE deposits along the dermal-epidermal junction had a higher Bullous Pemphigoid Disease Area Index (BPDAI) score compared to patients without linear IgE deposits.4 A direct pro-inflammatory effect of IgE on BMZ has also been proposed. [Extracted from the article]
- Published
- 2021
- Full Text
- View/download PDF